Open AccessPhase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
Author(s) -
Albert Lai,
Anh Tran,
Phioanh L. Nghiemphu,
Whitney B. Pope,
Orestes E. Solis,
Michael T. Selch,
Emese Filka,
William H. Yong,
Paul S. Mischel,
Linda M. Liau,
Surasak Phuphanich,
Keith L. Black,
Scott Peak,
Richard M. Green,
Cynthia E. Spier,
Tatjana Kolevska,
Jonathan Polikoff,
Louis Fehrenbacher,
Robert M. Elashoff,
Timothy F. Cloughesy
Publication year - 2010
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2010.30.2729
Subject(s) - temozolomide , medicine , bevacizumab , cohort , oncology , radiation therapy , prospective cohort study , glioblastoma , cancer , phases of clinical research , toxicity , surgery , chemotherapy , cancer research
This open-label, prospective, multicenter single-arm phase II study combined bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of newly diagnosed glioblastoma (GBM). The objectives were to determine the efficacy of this treatment combination and the associated toxicity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom